Lingke
X

 

      +86 0571-87711179

ychen1@lynkpharma.com

Lynk Pharmaceuticals Co., Ltd.    |   浙ICP备19010130号-2   |   Powered by www.300.cn    |   Manager 

CONTACT US

website

Search

291 Fucheng Road, Bldg 5-402, Jianggan, Hangzhou,
Zhejiang 310018, China

Lynk Pharmaceuticals Announced First Patient Dosed in Phase II Clinical Study of LNK01001
{{= $!info.name}}
Lynk Pharmaceuticals Announced First Patient Dosed in Phase II Clinical Study of LNK01001
Lynk Pharmaceuticals announced the completion of Series B financing of $50 million
{{= $!info.name}}
Lynk Pharmaceuticals announced the completion of Series B financing of $50 million
Lynk Pharmaceuticals Announced First Patient Dosed in Phase I Clinical Study of Its Triple-Kinase Inhibitor LNK01002
{{= $!info.name}}
Lynk Pharmaceuticals Announced First Patient Dosed in Phase I Clinical Study of Its Triple-Kinase Inhibitor LNK01002
Lynk Pharmaceuticals Announced Clinical Approval in China of Its New Class I Drug LNK01003
{{= $!info.name}}
Lynk Pharmaceuticals Announced Clinical Approval in China of Its New Class I Drug LNK01003
Lynk Pharmaceuticals Appoints Dr. Wang Weigand as Chief Medical Officer
{{= $!info.name}}
Lynk Pharmaceuticals enters exclusive licensing agreements develop RAS inhibitors with a novel MOA
{{= $!info.name}}
HANGZHOU, China, July 27, 2020 /PRNewswire/ -- Lynk Pharmaceuticals is pleased to announce exclusive licensing agreements with Kobe 
University and RIKEN Research Institute to develop RAS inhibitors with a novel MOA.
上一页
1
2
3